Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis

Table 3 Summary of adverse events, n (%)

	Before PSM				After PSM
	Triple therapy group (n = 324)		AIPB group (n = 118)		Triple therapy group (n = 88)		AIPB group (n = 88)
	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4
Fever	67 (20.7)	23 (7.1)	4 (3.4)	2 (1.7)	20 (22.7)	8 (9.1)	4 (4.5)	0 (0)
Nausea	100 (30.9)	0 (0)	6 (5.1)	0 (0)	24 (27.3)	0 (0)	5 (5.7)	0 (0)
Vomit	32 (9.9)	15 (4.6)	7 (5.9)	6 (5.1)	7 (8.0)	3 (3.4)	6 (6.8)	4 (4.5)
Abdominal pain	97 (29.9)	162 (50.0)	18 (15.3)	18 (15.3)	24 (27.3)	44 (50.0)	15 (17.0)	13 (14.8)
ALT increased	79 (24.4)	125 (38.6)	32 (27.1)	39 (33.1)	27 (30.4)	33 (37.5)	22 (25.0)	29 (33.0)
AST increased	130 (40.1)	161 (49.7)	36 (30.5)	44 (37.3)	40 (45.5)	49 (55.7)	26 (29.5)	34 (38.6)
Hyperbilirubinemia	37 (11.4)	7 (2.2)	7 (5.9)	11 (9.3)	10 (11.4)	0 (0)	4 (4.5)	8 (9.1)
Anemia	37 (11.4)	8 (2.5)	7 (5.9)	4 (3.4)	11 (12.5)	1 (1.1)	5 (5.7)	3 (3.4)
Neutropenia	86 (26.5)	20 (6.2)	9 (7.6)	12 (10.2)	29 (33.0)	5 (5.7)	5 (5.7)	9 (10.2)
Thrombocytopenia	103 (31.8)	90 (27.8)	27 (22.9)	20 (16.9)	24 (27.3)	16 (18.2)	20 (22.7)	13 (14.8)
Bleeding	48 (14.8)	3 (0.9)	1 (0.8)	1 (0.8)	12 (13.6)	1 (1.1)	1 (1.1)	1 (1.1)
Diarrhea	62 (19.1)	60 (18.5)	22 (18.6)	3 (2.5)	17 (19.3)	5 (5.7)	17 (19.3)	3 (3.4)
Hoarseness	80 (24.7)	0 (0)	13 (11.0)	0 (0)	21 (23.9)	0 (0)	10 (11.4)	0 (0)
Rash	92 (28.4)	4 (1.2)	28 (23.7)	4 (3.4)	24 (27.3)	0 (0)	20 (22.7)	3 (3.4)
HFS	69 (21.3)	9 (2.8)	19 (16.1)	18 (15.3)	18 (20.5)	1 (1.1)	14 (15.9)	11 (12.5)
Hypertension	76 (23.5)	11 (3.4)	31 (26.3)	34 (28.8)	22 (25.0)	3 (3.4)	23 (26.1)	27 (30.7)
RCCEP	42 (13.0)	14 (4.3)	16 (13.6)	6 (5.1)	11 (12.5)	5 (5.7)	13 (14.8)	6 (6.8)
Hypothyroidism	64 (19.8)	8 (2.5)	2 (1.7)	0 (0)	18 (20.5)	2 (2.3)	0 (0)	0 (0)
Fatigue	32 (9.9)	31 (9.6)	4 (3.4)	4 (3.4)	6 (6.8)	8 (9.1)	3 (3.4)	2 (2.3)
Hepatitis	10 (3.1)	1 (0.3)	0 (0)	0 (0)	5 (5.7)	1 (1.1)	0 (0)	0 (0)
Coma	0 (0)	2 (0.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

AFP: Alpha-fetoprotein; AIPB: Angiogenesis inhibitors and programmed cell death protein 1/programmed cell death ligand 1 blockers; triple therapy: Hepatic arterial infusion chemotherapy plus angiogenesis inhibitors and programmed cell death protein 1/programmed cell death ligand 1 blockers; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HFS: Hand-foot syndrome; RCCEP: Reactive cutaneous capillary endothelial proliferation.